HCV Treatment: The current treatment for hepatitis
C, including outcomes, side effects and treatment of various HCV populations
·
Consensus Interferon
o
355. Hepatitis C Virus (HCV) Treatment
Outcomes with Consensus Interferon with or without Ribavirin in
Peginterferon/Ribavirin Non-responders/Relapsers: Results from National
Clinical Practice Settings (updated
o
541. Consensus
Interferon Therapy for Hepatitis C Recurrence After Pegylated Intereferon
Failure Post Liver Transplant (updated
o
1332. U.S. multicenter pilot study of daily
consensus interferon (infergen) plus ribavirin for “difficult-to-treat” HCV
genotype 1 patients: tolerance and on-therapy virologic response. (updated
·
Disease Progression
o
243. Positive Impact of Antiviral Therapy on
the Long Term Outcome of Chronic Hepatitis C Patients with Cirrhosis (updated
o
319. Hepatocellular carcinoma in long-term
sustained virologic responders to antiviral treatment for chronic hepatitis C
(updated
o
338. Bone mineral density and metabolism in
non-cirrhotic patients with chronic hepatitis C before and after antiviral
therapy with pegylated interferon α and ribavirin: a prospective
controlled study (updated
·
Extrahepatic
Manifestations
o
236. Rituximab combined with
Peg-Interferon-Ribavirin in refractory HCV-associated cryoglobulinemia
vasculitis. (updated
o
331. Hepatitis C Associated Systemic
Cryoglobulinemia: Successful Treatment With Plasma Exchange
·
General
o
263. Morphological analysis and assessment
of HCV-RNA and ribavirin concentration in seminal fluid of chronic hepatitis C
patients undergoing antiviral combination therapy (updated
o
265. Improved Response Rates with Treatment
Extension to 72 weeks in Slow Responders to Peginterferon and Weight-Based
Ribavirin in Chronic Hepatitis C Virus (HCV) Infection (updated
o
268. Treatment of recently acquired
hepatitis C infection in injecting drug users: Preliminary results from The
Australian Trial in Acute Hepatitis C (ATAHC) (updated
o
275. Insulin Resistance (IR) defined by the
homeostasis model of assessment insulin resistance (HOMA-IR) index has a direct
effect on early viral kinetics during Pegylated-Interferon therapy for Chronic
Hepatitis C (updated
o
281. Real-life Rates of Treatment Completion
for HCV(updated
o
291. Bezafibrate treatment for chronic
hepatitis C after failure of previous combination therapy with Interferon and
Ribavirin (updated
o
293. Early reduction of Ribavirin leads to
retardation of viral clearance and affects SVR (updated
o
299. Evaluation of a multidisciplinary
support program in hepatitis C treatment (updated
o
315. Hepatitis C treatment outcomes in the
Rhode Island Department of Corrections (updated
o
347. Description of Patients with Viral
Breakthrough During PEG IFN and Ribavirin Treatment for Chronic HCV Genotype 1
(updated
o
348. Extending antiviral treatment for 12
months after HCV-RNA clearance is associated with a high response rate in
difficult-to-treat HCV patients (updated
o
1314. Treatment of Alcoholic HCV Patients
with Acetaminophen 4 g/Day for 5 Days Does Not Affect Hepatic Tests Compared to
Placebo (updated
o
1326. A 52 week multi-centre, randomized,
double-blind placebo-controlled trial evaluating the efficacy and safety of
glycyrrhizin in patients with chronic hepatitis C not responding to IFNα
or PEG-IFN plus ribavirin therapy (updated
o
1384. SVRScore: a Novel and Highly
Predictive Score for SVR Prediction in Chronic Hepatitis C Genotype 1 Infected
Patients (updated
·
Herbal Treatments
o
1383. Botanical Medicines for Hepatitis C
·
HIV/HCV Coinfection
o
264. Fosamprenavir in HAART schedule induces
a rapid virological and biochemical response to HCV coupled to Th1 boosting in
HIV/HCV coinfected patients (updated
o
342. Negative Impact of Abacavir on Response
to pegIFN plus RBV in HIV/HCV Coinfected Patients (updated
o
343. Sustained Virologic Response (SVR) To
Peg-Interferon Plus Ribavirin In Genotype-4 HCV-HIV Coinfected Patients (updated
o
345. Re-treatment with Pegylated Interferon
plus Weight-Adjusted Ribavirin in HIV+ Patients with Chronic Hepatitis C: The
PILOT-NR Study (updated
·
IDU
o
295. Treatment Uptake and Outcomes Among
Current and Former Injection Drug Users (IDUs) Receiving Directly Observed Therapy
Within a Multidisciplinary Group Model for the Treatment of Hepatitis C Virus
(HCV) Infection (updated November 4, 2007)
o
296. Infrequent Hepatitis C Virus (HCV) Re-infection
after Sustained Virological Response (SVR) Among Current and Former Injection
Drug Users (IDUs) Having Received Treatment for HCV Infection (updated
o
346. Feasibility of combination therapy for
chronic hepatitis C in IVDU in the framework of an heroin detoxification
protocol (updated
·
Liver Transplantation
o
239. Preemptive Treatment of HCV After Liver
Transplantation Is Unjustified Except for Genotype 3a.
·
Methadone
o
253. Opioid maintenance therapy is not
associated with treatment failure to hepatitis C therapy in a large German
multicentre cohort (updated
·
Pegasys
o
25.
Prophylactic Peginterferon Alfa-2a/Ribavirin vs No Prophylaxis Following
Orthotopic Liver Transplantation (OLT) for Hepatitis C: 24-Week Virologic and
Safety Responses (updated
o
233. An Open Label, Comparative, Multicenter
Study Of Peginterferon Alfa-2a Plus Ribavirin in The Treatment Of Patients With
Chronic Hepatitis C/Hepatitis B Co-Infection Versus Those With Chronic
Hepatitis C (updated
November 12, 2007)
o
234. Early discontinuation of ribavirin in
HCV-2 and HCV-3 patients responding to Peg-interferon alfa-2a and ribavirin
(updated
o
237. Twice vs Once Weekly Dosing of
Peginterferon Alfa 2a in Chronic HCV Genotype 1 Infection: Analysis of Early
Viral Kinetics (updated
o
245. Efficacy and Safety of Escitalopram for
the Prevention of Depressive Episodes Induced by Peg-Interferon Alpha2a and
Ribavirin in Chronic Hepatitis C Patients. A Double-Blind, Randomized,
Placebo-Controlled Trial. (updated
o
251. Response to high ribavirin dose in
combination with peg-INF alfa-2a for treatment of HCV genotype 1 previous
non-responders (updated
o
276. Treatment of chronic hepatitis C with
peginterferon alfa-2a (40KD) (PEG) and Ribavirin (RBV) in naïve patients with
HIV-HCV co-infection in the real-life setting in Germany (updated
o
321. High rates of sustained virological
response (SVR) in patients >50 years infected with HCV genotype 1 with
positive prognostic factors treated with peginterferon alfa-2a (40KD)
(PEGASYS®) and ribavirin (COPEGUS®) (updated
o
328. PEG Interferon ALFA-2A Monotherapy in
Dialysis Patients Infected with Hepatitis C Virus (updated
o
337. PEG-IFN alfa-2A plus Ribavirin is
Superior Compared to High Dose Consensus Interferon (CIFN) and Ribavirin in the
Treatment of Patients with Chronic Hepatitis C (updated
o
1301. Response-guided therapy in a
prospective trial of peginterferon alfa-2a (40KD)/ribavirin treatment in
patients with genotypes 1 or 4 (updated
o
1309. Final Results of Patients Receiving Peg-Interferon-Alfa-2a
(Peg-IFN) and Ribavirin (RBV) After a 14-Day Study of the Hepatitis C Protease
Inhibitor Telaprevir (VX-950), With Peg-IFN
o
1329. Viral Kinetics Of HCV Genotype 4
During Pegylated Interferon Alpha 2a –Ribavirin Therapy
o
1327. Comparison of peginterferon alfa-2a
and ribavirin for 12 or 24 weeks in patients with HCV genotype 2 or 3: the CLEO
trial (updated
·
PEG-Intron
o
246. Response to Peginterferon alfa-2b +
Ribavirin Combination Therapy in Genotype 2 and 3 Patients With Poor Baseline
Prognostic Factors: Results of the Canadian POWeR Program (updated
o
261. Relapse rates among HCV Genotype 1
early virological responders in a retrospective community-based cohort of
patients treated with PEGETRON® in British Columbia, Canada (updated
o
262. Viral and STAT kinetics in patients
with chronic hepatitis C treated with pegylated interferon a-2b plus ribavirin
(updated
o
272. Time to HCV RNA Negativation in Hepatitis
C Virus (HCV) Type 1-Infection During PEG-Interferon-alpha-2B plus Ribavirin
Therapy: Differences in Relation to the Assay Sensitivity (Indiv-1 Study Group)
(updated
o
302. Consistency of Sustained Virologic
Response (SVR) Across Weight Categories: Results From the Canadian POWeR (Peginterferon
alfa-2b Prospective Optimal Weight-based Dosing Response) Program (updated
o
325. Patient education improves adherence to
peginterferon α-2b and ribavirin in chronic genotype 2 or 3 hepatitis C
virus infection: A prospective, real-life study (CHEOBS Study) (updated
o
326. Peginterferon alfa-2b and ribavirin
treatment of patients with chronic hepatitis C and normal versus elevated
aminotransferase levels – final results of a prospective open trial (updated
o
336. Treatment and outcome of genotype 4
chronic hepatitis C patients with PegInterferon alfa 2b and Ribavirin in the
clinical setting in Germany (updated
o
353. Combination therapy with pegylated
interferon alfa-2b and ribavirin for patients with chronic hepatitis C and
normal aminotransferase levels (updated
o
1311. Long-term Low Dose Treatment with
Pegylated Interferon alpha 2b leads to a significant Reduction in Fibrosis and
Inflammatory Score in Chronic Hepatitis C Nonresponder Patients with Fibrosis
or Cirrhosis (updated
November 3, 2007)
·
Predictors of Treatment
Response
o
249. Pretreatment insulin sensitivity
contributes to the treatment response to peginterferon plus ribavirin
combination therapy for patients with chronic hepatitis C (updated
o
284. Iron Depletion and Response to
Interferon in Chronic Hepatitis C (HCV) : A Meta-Analysis (updated
o
303. Rapid Virological Response at Week 4 is
the Best Predictor of Treatment Outcome in Patients with Chronic Hepatitis C: A
Multivariate Analysis (updated November 3, 2007)
o
304. Assessment of Both Virological Response
at Week 4 and at Week 12 Optimizes Prediction of Treatment Outcome in Patients
with Chronic Hepatitis C Treated with Peginterferon alfa-2B Plus Ribavirin (updated
o
340. Factors Impacting SVR in HCV Genotype 1
Patients with EVR and Week 24 Negativity (updated
·
Side Effects